Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
North Carolina officials announced the January 2014 launch of a statewide telepsychiatry plan to improve access to mental health professionals. North Carolina is investing $4 million over two years in the project, which is overseen by the state's Department of Health and Human Services Office of Rural Health and Community Care.
MyJourney Compass, an Office of the National Coordinator for Health IT (ONC) pilot project launched on Aug. 12, is aiming to help patients navigate the cancer treatment process and become more engaged in their healthcare decisions.
Clinicians continue to adopt mobile computing devices at a rapid rate this year, with nearly 90 percent expected to use smartphones in 2014 and almost as many using tablets.
The Federal Health Architecture released CONNECT 4.2, an enhanced version of CONNECT 4—the dynamic open source platform designed to enable secure health information exchange.
A clinical study launched by Scripps Translational Science Institute will investigate whether the integration of wireless technologies, online social networks and medicine can directly impact healthcare spending.
The Health Resources and Services Administration awarded six health center networks about $3 million in Affordable Care Act funds to facilitate adoption of health IT.
Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.
RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.
